Publications by Jennie Olofsson
Peer reviewed
Articles
[1]
S. Mravinacová et al., "Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases," Scientific Reports, vol. 15, no. 1, 2025.
[2]
A. Ullgren et al., "Altered plasma protein profiles in genetic FTD : a GENFI study," Molecular Neurodegeneration, vol. 18, no. 1, 2023.
[3]
J. Olofsson et al., "Array-Based Multiplex and High-Throughput Serology Assays," Methods in Molecular Biology, vol. 2628, pp. 535-553, 2023.
[4]
S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, pp. 72-80, 2022.
[5]
S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, pp. e0262169-e0262169, 2022.
[6]
S. Bergström et al., "A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers : a GENFI study," Molecular Neurodegeneration, vol. 16, no. 1, 2021.
[7]
A. Månberg et al., "Altered perivascular fibroblast activity precedes ALS disease onset," Nature Medicine, vol. 27, no. 4, 2021.
[8]
J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.
[9]
J. Remnestål et al., "Association of CSF proteins with tau and amyloid beta levels in asymptomatic 70-year-olds," Alzheimer's Research & Therapy, vol. 13, no. 1, 2021.
[10]
J. Dillner et al., "High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers," The Journal of Infectious Diseases, vol. 224, no. 1, pp. 14-20, 2021.
[11]
S. Bergström et al., "Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease," Annals of Clinical and Translational Neurology, vol. 8, no. 7, pp. 1456-1470, 2021.
[12]
S. Hober et al., "Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay," Clinical & Translational Immunology (CTI), vol. 10, no. 7, 2021.
[13]
J. Remnestål et al., "Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers," Translational Neurodegeneration, vol. 9, no. 1, 2020.
Chapters in books
[14]
E. Pin et al., "Array-based profiling of proteins and autoantibody repertoires in CSF," in Cerebrospinal Fluid (CSF) Proteomics, : Humana Press Inc., 2019, pp. 303-318.
Non-peer reviewed
Other
[15]
S. Bergström et al., "A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study," (Manuscript).
[16]
S. Mravinacová et al., "Addressing inter-individual variability in CSF levels of brain-derived proteins across neurodegenerative diseases," (Manuscript).
[17]
S. Bergström et al., "Multi-cohort protein profiling reveals higher levels of six brain-enriched proteins in Alzheimer’s disease patients," (Manuscript).
Latest sync with DiVA:
2025-03-16 03:31:11